Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An update from ProText Mobility ( (TXTM) ) is now available.
On Nov. 17, 2025, Protext Mobility, Inc. announced a strategic Letter of Intent with TruLeaf that combines TruLeaf’s nanotechnology with Protext’s kettle technology to boost bioavailability, cut production costs, and make CBD-based products faster-acting and more effective. The alliance also involves TruLeaf providing product samples, initial inventory and infrastructure support, while positioning Protext to treat CBD-based active pharmaceutical ingredients as real-world balance-sheet assets under IFRS/GAAP and explore future tokenization and stablecoin applications, strengthening the company’s financial profile and competitive standing in compliant, THC-free CBD markets.
The Letter of Intent underscores Protext’s goal of using Farm Bill–compliant, THC-free CBD FECO to gain a regulatory edge and enhance shareholder value through improved margins and potential new digital-asset-based financing models. TruLeaf’s endorsement and operational backing serve as market validation for Protext’s technology and mission, signaling an effort to scale operations, accelerate market entry, and reinforce its positioning at the intersection of plant-based therapeutics and innovative financial structures tied to CBD-derived assets.
More about ProText Mobility
Protext Mobility, Inc. is a biotechnology company focused on research, testing, and development of highly bioavailable, nanotechnology-based botanical formulations for nutraceutical and pharmaceutical applications. Using proprietary live plant extraction technologies, it aims to advance plant-based therapeutics to address global wellness and health needs.
Current Market Cap: $58.51M
Find detailed analytics on TXTM stock on TipRanks’ Stock Analysis page.